
Opinion|Videos|November 27, 2024
Patient Selection and Personalized Treatment Strategies
Key Takeaways
- Transitioning from IV to oral medications requires careful management of adherence, side effects, and therapeutic efficacy to ensure optimal patient outcomes.
- Patient-specific factors, such as comorbidities and drug interactions, are critical in optimizing treatment during the transition from IV to oral medications.
An overview of challenges in transitioning from IV to oral medications and guidance on identifying NSCLC patient populations most likely to benefit from HER2-directed therapies through informed patient selection strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What challenges may exist when transitioning from IV to oral medications?
- Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
3
FDA Expands Sotatercept Indication for PAH
4
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
5
















































